“Simeglutide” refers to Simeglutide, the hypoglycemic principle of Simeglutide is to stimulate insulin secretion and inhibit glucagon secretion in a glucose concentration-dependent manner through the activation of glucagon-like peptide-1 receptor, and at the same time, increase the glucose uptake of muscle and adipose tissue and inhibit hepatic glucose production to exert hypoglycemic effect, and It inhibits gastric emptying and suppresses appetite. This drug is mainly used for glycemic control in adult population with type 2 diabetes mellitus, and is suitable for patients with poor glycemic control despite treatment with metformin and/or sulfonylureas on the basis of dietary control and exercise. Pay attention to the presence of nausea, vomiting, diarrhea and other adverse reactions during the use of the drug. The drug is contraindicated in people who are allergic to the components of the drug, in patients with a personal past or family history of medullary thyroid carcinoma, in patients with multiple endocrine neoplasia syndrome type 2. If there is a need to use Simeglutide, it is recommended to apply it under the guidance of professional doctors in regular hospitals and avoid unauthorized use of the drug.